Physician

Family Medicine

Robert A. Hodgson works in the field of Family Medicine. He researched medicine at University of Oklahoma College of Medicine. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Doctor Robert A. Hodgson, MD is a published doctor and has 28 publications published. The lastest was: 'Discovery of aminoquinazoline derivatives as human A2A adenosine receptor antagonists.' Robert Hodgson accepts Medicare.

Publications

---

• Discovery of aminoquinazoline derivatives as human A2A adenosine receptor antagonists.
• Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
• Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
• Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model.
• MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A2A ant...
• A2A receptor antagonists do not induce dyskinesias in drug-naive or l-dopa sensitized rats.
• Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS A? Reduction.
• Adenosine A(2A) Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease.
• The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): Compa...
• Characterization of the selective mGluR1 antagonist, JNJ16259685, in rodent models of movement and coordination.
• Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders.
• Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)...
• The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 22...
• Duration of ultrasonic vocalizations in the isolated rat pup as a behavioral measure: sensitivity to anxiolytic and antidepressant drugs.
• Training-induced and electrically induced potentiation in the neocortex.
• Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.
• Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson''s disease.
• The antipsychotic drug, fluphenazine, effectively reverses mechanical allodynia in rat models of neuropathic pain.
• The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia.
• Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species.
• Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.
• Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.
• Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior.
• The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in r...
• The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
• The effect of caffeine to increase reaction time in the rat during a test of attention is mediated through antagonism of adenosine A2A receptors.
• Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.

Schools

---

• University Of OklahomaTulsaCollege Of Medicine

• John Peter Smith Hospital

Doctors Specialties

---

• Family Medicine

Accepted Insurances

---

• Aetna HMO
• Choice Plus POS II
• Blue Card PPO
• Blue Choice
• Cigna HMO
• Cigna PPO
• Great West Healthcare-Cigna PPO
• Open Access Plus
• First Health (Coventry Health Care) PPO
• Choice Care PPO
• Preferred PPO
• Choice Plus POS
• Navigate HMO
• Navigate POS
• Options PPO

Awards

---

• CMS Meaningful Use Stage 1 Certification

Education

---

• John Peter Smith Hospital
• University of Oklahoma College of Medicine

Hospital

---

• North Hills Hospital

Drug Facts

---

NPI NUMBER		1437252459
NPPES Provider LastName		HODGSON
NPPES Provider FirstName		ROBERT
NPPES Provider ZIPCode		761374437
NPPES Provider State		TX
Specialty Description		Family Practice
Total Claim Count		2600.0
Distinct Opioid Count		2.0
Opioid Claim Count		64.0
Percent Opioid Claims		2.46

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1437252459
Last Name Of The Provider	HODGSON
First Name Of The Provider	ROBERT
View All

Similar Doctors

---

	Dr. Steven Hardee, MD This Doctor is OpenDoctor Recommended.
	Dr. Sarah O. Ashitey, MD
	Dr. Shahryar Balakhani, DO
	Dr. Mark J. Nelson, MD
	Dr. Kristin Garner, MD
	Dr. Francis K. Mascarenhas, MD This Doctor is OpenDoctor Recommended.
	Dr. Samuel C. Dvorak, MD
	Dr. Jason A. Mogonye, MD This Doctor is OpenDoctor Recommended.
	Dr. Benjamin R. Respess Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Peter G. McDougall, MD This Doctor is OpenDoctor Recommended.
	Dr. Harold H. Fain Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Randal L. Brown, MD This Doctor is OpenDoctor Recommended.
	Dr. Matthew L. Rios, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog